Short Interest in Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) Grows By 21.0%

Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) was the recipient of a significant growth in short interest in March. As of March 13th, there was short interest totaling 4,044,938 shares, a growth of 21.0% from the February 26th total of 3,341,948 shares. Approximately 19.0% of the company’s stock are sold short. Based on an average daily volume of 1,121,408 shares, the days-to-cover ratio is presently 3.6 days.

Institutional Trading of Citius Pharmaceuticals

A number of hedge funds have recently added to or reduced their stakes in the stock. XTX Topco Ltd purchased a new stake in shares of Citius Pharmaceuticals during the second quarter worth approximately $32,000. NewEdge Advisors LLC acquired a new position in Citius Pharmaceuticals in the 2nd quarter valued at $40,000. Asset Advisory Group Inc. acquired a new stake in shares of Citius Pharmaceuticals in the 4th quarter worth $46,000. Finally, Heights Capital Management Inc. purchased a new stake in shares of Citius Pharmaceuticals in the fourth quarter valued at about $622,000. 16.88% of the stock is owned by institutional investors and hedge funds.

Citius Pharmaceuticals Trading Up 32.3%

Shares of Citius Pharmaceuticals stock traded up $0.22 during trading on Tuesday, reaching $0.90. The company’s stock had a trading volume of 1,953,920 shares, compared to its average volume of 556,793. The company has a 50-day moving average price of $0.79 and a two-hundred day moving average price of $1.04. Citius Pharmaceuticals has a fifty-two week low of $0.63 and a fifty-two week high of $2.48. The firm has a market cap of $20.14 million, a PE ratio of -0.37 and a beta of 1.51.

Citius Pharmaceuticals (NASDAQ:CTXR) last issued its quarterly earnings data on Friday, February 13th. The company reported ($0.38) earnings per share (EPS) for the quarter. On average, analysts predict that Citius Pharmaceuticals will post -4.5 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

CTXR has been the topic of a number of research analyst reports. D. Boral Capital reissued a “buy” rating and set a $6.00 price objective on shares of Citius Pharmaceuticals in a report on Wednesday, March 11th. Wall Street Zen raised shares of Citius Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research report on Saturday, December 27th. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Citius Pharmaceuticals in a report on Friday. One analyst has rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $6.00.

About Citius Pharmaceuticals

Citius Pharmaceuticals is a clinical‐stage specialty pharmaceutical company focused on the development and commercialization of critical care products and novel drug delivery systems. Headquartered in Cranford, New Jersey, the company aims to address unmet medical needs in acute care, hospital‐acquired infections and subcutaneous delivery of biologics. Citius operates as a Delaware corporation and trades on the NASDAQ under the symbol CTXR.

One of the company’s leading assets is Mino-Lok, an antibiotic lock solution designed to treat catheter‐related bloodstream infections without catheter removal.